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Summary
Background: Refractory ascites (RA) is a frequent complication of cirrhosis, requiring
large volume paracentesis or placement of a transjugular intrahepatic portosystemic
shunt (TIPSS). The automated low-flow ascites pump (alfapump, Sequana Medical
AG, Zurich, Switzerland) is an innovative treatment option for patients with RA.
Aim: To assess safety and efficacy of this treatment in patients with a contraindica-
tion to TIPSS.
Methods: Fifty-six patients (43 males; mean age 62 years) from centres in Ger-
many, Switzerland, UK and Spain were included and followed for up to 24 months.
Complications, device deficiencies, paracentesis frequency and patient survival were
recorded.
Results: At the time of this analysis, 3 patients completed the 24-month observa-
tion period, monitoring of 3 was ongoing, 9 underwent liver transplantation, 17
patients were withdrawn due to serious adverse events and 23 patients died. Most
frequently observed technical complication was blocking of the peritoneal catheter.
Twenty-three pump-related reinterventions (17 patients) and 12 pump exchanges
(11 patients) were required during follow-up. The pump system was explanted in
48% of patients (in 17 patients due to serious adverse events, in 9 at the time of
liver transplantation and in 1 due to recovery from RA). Median frequency of para-
centesis dropped from 2.17 to 0.17 per month.
Conclusions: The alfapump can expand therapeutic options for cirrhotic patients
with RA. Continuous drainage of ascites in a closed loop automated system led to
significant reduction in paracentesis frequency. Technical and procedural improve-
ments are required to reduce the rate of adverse events and reinterventions.
https://clinicaltrials.gov/ct2/show/NCT01532427
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1 | INTRODUCTION
Refractory ascites (RA) is a serious complication of cirrhosis, devel-
oping in 5%-10% of patients with ascites every year.1 RA is associ-
ated with poor prognosis and a 6-month transplant-free survival of
only 65.3%.2 Treatments for RA are considered short-to-medium
term solutions while awaiting potential liver transplantation. Treating
tense ascites before transplantation may also prevent further deteri-
oration of a patient’s condition, including appetite loss, inadequate
nutrition, impaired gut motility or sarcopenia,3 and relieve discom-
fort.
Initial RA treatment consists of repeat large volume paracentesis
(LVP) in combination with albumin substitution.1 Although the risk of
peri-procedural complications from repeat paracentesis is low,4-6 and
circulatory dysfunction can be prevented with intravenous albumin
replacement,7-9 this treatment option poses a substantial burden on
the patient as well as on the medical team and is associated with
high economic cost.10
The placement of a transjugular intrahepatic portosystemic shunt
(TIPSS) offers an alternative to repeat LVP. Four randomised clinical
trials, comparing bare TIPSS to repeat paracentesis, have been
reported.11-14 A meta-analysis of these studies2 showed that TIPSS
is an effective treatment and markedly decreased the number of
paracenteses required. However, 42% of TIPSS patients experienced
recurrence of tense ascites. Additionally, long-term survival benefits
and the development of encephalopathy have been debated.15-17 A
recent randomised controlled trial in mostly Child B patients younger
than 65 years comparing covered TIPSS with LVP plus albumin
showed an improved transplant-free survival in the TIPSS group,
without significant difference in the occurrence of hepatic
encephalopathy.18
However, a significant proportion of patients with RA show indi-
cators of poor post-TIPSS prognosis, namely previous episode of
hepatic encephalopathy, higher age, platelet count below 75 9
10E9/L and bilirubin >50 lmol/L.19 Hence, novel treatment options
for RA represent an important requirement in hepatology.
The aim of this study was to prospectively assess safety and effi-
cacy in cirrhotic patients with RA, who had a contraindication to
TIPSS and were therefore treated with an alfapump.
The automated low-flow ascites pump (alfapump, Sequana Medi-
cal AG, Zurich, Switzerland) (Figure 1) is a fully implantable pump
system, developed to transfer ascitic fluid from the abdominal cavity
to the urinary bladder via tunnelled peritoneal and bladder catheters
that are connected to the subcutaneous pump. The alfapump con-
tains 4 pressure sensors to monitor the abdominal pressure and the
bladder pressure and to provide information on flow rate and system
behaviour. A pumping cycle is initiated only if the bladder pressure
is below a certain threshold. At the same time, pumping is immedi-
ately stopped when the pressure in the peritoneal cavity drops sig-
nificantly which indicates that the alfapump cannot access sufficient
fluid.
The pump type used within the alfapump is a so called gear
pump where fluid is moved forward in between rotating gears. To
transport a desired volume, a dedicated amount of motor turns is
necessary. In combination with the motor speed, this leads to the
flow rate of the alfapump. When ascites is transported, it moves
past several pressure sensors. The changes in pressure sensor values
confirm fluid is actually being transported.
The physician in charge of following up a patient implanted with
the alfapump uses the alfapump Programmer, a computer running
FlowControl software. FlowControl allows to program the target
daily volume, the pumping times throughout the day, the frequency
of pumping and to switch the alfapump on and off.
A wireless induction system is used to charge the pump in general
twice daily. Pump parameters including operating time, cycle fre-
quency and daily ascites volume can be set as clinically required for
each patient with a wireless controller. Information from the device
about the effective ascites volume that has been transferred into the
bladder as well as possible dysfunctions is transmitted automatically
via the charger docking station to the manufacturer and is periodically
reported to the treating physician. Thus, pump status is continuously
monitored and updated, and adjustments to the pump programming
by the physician are based on actual patient and pump conditions.
The safety and efficacy of the alfapump system were investigated
in the PIONEER study.20 The authors reported a reduction in the med-
ian frequency of paracentesis from 3.4 to 0.2 per month and an ade-
quate safety profile, so that this device was approved for commercial
use in Europe in 2011. Results of the first randomised clinical trial
comparing the effect of the alfapump system with standard of care
large volume paracenteses have been published recently.21 Compared
to the standard of care group, the alfapump system significantly
reduced the need for LVP and patients in the alfapump group had a
significant improvement in health-related quality of life after 3 months
as measured with the Chronic Liver Disease Questionnaire. Acute kid-
ney injury in the immediate post-operative phase and pump-related
reinterventions were the most prominent adverse events. In both
treatment groups, survival was similar.
F IGURE 1 Alfapump with peritoneal catheter (blue) and pigtail
bladder catheter (yellow)
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2 | MATERIALS AND METHODS
Ten European referral centres participated in this prospective obser-
vational study. Cirrhotic patients with RA presenting any contraindi-
cations to TIPSS received a treatment with the alfapump system. RA
was defined as diuretic-resistant or diuretic-intractable or as early
recurrence of ascites after paracentesis.22 Inability to operate the
charging system was considered an exclusion criteria. Patients on
treatment with the alfapump were followed up for at least
12 months and information about LVP, hepatic decompensations,
infections, death, adverse device events and liver transplant were
recorded prospectively. Blood chemistry, haematology data and
adverse events information was collected as part of standard clinical
practice (no study-specific tests were required).
The management of candidates for an alfapump implantation
was optimised with respect to nutritional support and screening/
treatment of oesophageal varices.23
One day prior to the implantation of the pump, a LVP was per-
formed to void the abdominal cavity. Albumin was replaced according
to current guidelines.22 The peritoneal catheter was introduced into
the abdominal cavity just above the umbilicus. The entry point into the
abdominal cavity was closed using a tight purse-string suture to pre-
vent leakage of ascites. To facilitate positioning of the pigtail bladder
catheter, the bladder was filled retrograde with methylene-blue
coloured saline. The pigtail catheter was introduced into the bladder
with a removable introducer system. A subcutaneous pump pocket
was formed in the right upper quadrant of the abdomen to position
the pump. The pump pocket was just large enough to hold the pump
but small enough to prevent pump migration. Both the bladder and
the peritoneal catheter were connected to the pump via subcutaneous
tunnelling (Figure 5). Skin sutures were left in place for up to 3 weeks
in order to prevent wound dehiscence or ascites leakage.24
After implantation of the pump, long-term antibiotic prophylaxis
was administered, in most cases norfloxacin, 400 mg daily. Patients
were followed up weekly for the first month after implantation and on
an individual schedule as determined by the treating physician there-
after. Albumin administration was left to the discretion of the individ-
ual investigators, according to the current treatment guidelines.22,25
The maximum follow-up period for this analysis was set to 24 months,
excepting 2 patients who received last follow-up at 26.4 months.
Reintervention was defined as surgical replacement or correction
of either one or both alfapump system catheters (pump in situ) or a
revision of the pump pocket. Pump exchange comprised the
exchange of the alfapump with a new pump system within the same
surgical procedure. Explantation was defined as surgical removal of
the pump due to serious adverse event (SAE), transplantation or no
more need.
2.1 | Statistics
Results are reported as mean (SD) or as median (interquartile range,
IQR), as indicated. For survival analyses, Kaplan-Meier plots were
used. The follow-up schedule was at the discretion of the investigator
and laboratory data that were closest to the indicated time points
(baseline, 1, 3, 6, 12, 18 and 24 months) were analysed. Statistical
analyses were performed using SPSS V23.0 Armonk, NY, USA.
“alfapump system survival” was defined as elapsed time from
pump implantation to the time of explant for pump-related reasons.
Pump replacement due to pump malfunction was counted as an
event having occurred at time of replacement. Explant due to an
SAE was counted as an event having occurred at time of explant.
Explants due to OLT or due to an SAE unrelated to the pump
system were censored at time of explant.
This study was approved by the required Independent Ethical Com-
mittees and Institutional Review Boards of the participating centres
and all patients gave their written consent to participate in this study.
3 | RESULTS
Fifty-six patients (43 men, 13 women, mean age 62 years) were
enrolled in this study—30 in Switzerland (Bern, 25; and Geneva, 5),
21 in Germany (Leipzig, 7; Frankfurt am Main, 6; Homburg, 3; Dres-
den, 2; W€urzburg, 2; and Jena, 1), 3 in the United Kingdom (New-
castle) and 2 in Spain (Barcelona). All pumps were implanted under
general anaesthesia. Median duration of surgery was 60 min (50-69).
Median hospital stay following implantation was 7 days.3-14
Patients’ baseline characteristics are presented in Table 1. Med-
ian MELD score was 13 and mean Child-Pugh score was 8.9 (1.3).
Fifteen patients (24.8%) were Child-Pugh class C, 36 (64.3%) were
class B, and 5 had an unknown score. The median duration of ascites
prior to implantation of the alfapump system was 11.0 months
(8.0-19.0) with a median frequency of large volume paracenteses
over the previous 3 months of 2.17 per month (1.45-4.34) (Table 2).
3.1 | Outcome
Overall survival is shown in Figure 2. Mean actuarial survival was
12.8 months (95% CI 10.0-15.7) and median survival was
9.8 months. Patient disposition at the end of study (data cut-off) is
listed in Table 3. Twenty-three patients (41.1%) died during the
study, while 7 patients died after being withdrawn from the study
due to pump removal secondary to SAEs. The primary cause of all
deaths (during the study and after withdrawal) was progression of
cirrhosis with decompensation (Table 4). MELD score and Child-
Pugh score over time are summarised in Table S1.
3.2 | Device and procedure-related safety events
The most frequent device related event was clogging of the peri-
toneal catheter by proteinaceous debris and/or fibrin clots and aspi-
ration of the omentum (21 events in 13 patients). In 5 patients, the
peritoneal catheter was either displaced, disconnected, or twisted.
The bladder catheter was blocked or displaced in one case each.
There were 2 procedure-related problems involving wound dehis-
cence. Device and procedure-related events are listed in Table S2).
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Long-term ascites leakage did not occur in any patient, although
short-term leakage after implantation was common and not specifi-
cally monitored as it usually resolved quickly.
3.3 | Reinterventions, pump exchanges and pump
explantations
Seventeen patients (21.4%) required at least on reintervention (23
interventions in total) and 11 patients had a surgical pump replace-
ment (in total, 12 pumps were exchanged). The pump was
explanted in 27 cases. In 17 patients (30.4%), the pump was
explanted due to a SAE associated either with progressive liver dis-
ease, including infection (12 [21.4%]), or for reasons related to
device deficiency (5 [8.9%], including pump pocket infection [2],
clogged pump [1], and macroscopic haematuria [2]). In 9 of the 27
cases, the pump was explanted because patients received liver
transplants. In a single case, the patient was successfully treated
for chronic hepatitis C and recovered from RA, so that the pump
was explanted, because it was no longer necessary (Table 5). Out-
come after surgical revision (1-month survival) is specified in
Table 6 and Table S3. One-month recovery after surgical revision
was 100%, whereas 1 patient died 2 weeks after the exchange of
the pump system. In this patient, the pump had to be explanted
1 week after the exchange of the system due to a pump pocket
infection. Survival of the alfapump system after implant is pre-
sented in Figure 2. The median pump system survival in this study
was 13.6 months (95% CI 10.2-16.9 months).
3.4 | Liver and renal function
Blood chemistry and coagulation parameters are presented in Fig-
ure 3 and in Table S4. After the implantation of the pump system,
an increase in plasma creatinine could be observed (mean increase
of 20.2 lmol l1 at 1 month, 46.6 lmol l1 at 3 months as com-
pared to baseline). At 6 months, a further increase could only be
observed in patients with a less favourable outcome (non-long term
survivors). Similarly, serum albumin levels decreased slightly over
time (mean decrease of 1.4 g/L after 1 month, 2.3 g/L after
3 months and 3.2 g/L after 6 months). This effect was less
pronounced in long-term survivors).
3.5 | Efficacy: Large volume paracenteses after the
implantation
The frequency of LVP decreased to 0.17 per month (0.00-0.41) after
implantation (Table 2).
TABLE 1 Baseline characteristics
Number included in analysis 56
Median age in years (range) 62 (50-78)
Gender (%) 43 male (77)
13 female (23)
Body weight (kg), mean (SD) 77 (16.1)
BMI (kg/m2), mean (SD) 25.9 (4.7)
Aetiology of liver cirrhosis (%)
Alcohol 39 (69.7)
Hepatitis C 4 (7.1)
Cryptogenic 4 (7.1)
NASH 3 (5.4)
Cardiac 2 (3.6)
Autoimmune hepatitis 1 (1.8)
Drug-induced 1 (1.8)
HBV and AIH 1 (1.8)
HCV and HBV and Alcohol 1 (1.8)
History of hepatic encephalopathy (%)
Yes 21 (37.5)
No 31 (55.4)
Unknown/missing data 4 (7.1)
History of renal dysfunction (%)
Yes 26 (46.4)
No 23 (41.1)
Unknown/missing data 7 (12.5)
History of hepatorenal syndrome (%)
Prior episode of HRS 20 (35.7)
No prior episode of HRS 24 (42.9)
Unknown/missing data 12 (21.4)
History of SBP (%)
Yes 22 (39.3)
No 30 (53.6)
Unknown/missing data 4 (7.1)
History of urinary tract infection (%)
Yes 9 (16.1)
No 34 (60.7)
Unknown/missing data 13 (23.2)
Child-Pugh score, mean (SD) 8.9 (1.3)
B (7-9) (%) 36 (64.3)
C (10-15) (%) 15 (26.8)
Unknown/missing data (%) 5 (8.9)
MELD score
Median (n, range, Q1, Q3) 13 (53, 6-25, 9.5, 16)
Mean (SD) 13.6 (4.4)
Unknown/missing data (%) 3 (5.4)
(Continues)
TABLE 1 (Continued)
Blood values
Bilirubin (µmol l1), N = 54, mean (SD)
Median (IQR)
34.9 (32.9)
24.7 (16.0-40.0)
Creatinine (µmol l1), N = 56, mean (SD)
Median (IQR)
111.0 (47.1)
98.6 (83.4-119.5)
Albumin (g/L), N = 56, mean (SD)
Median (IQR)
31.0 (6.7)
31.5 (26.5-36.8)
INR, N = 54, mean (SD)
Median (IQR)
1.30 (0.22)
1.27 (1.14-1.42)
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Over a median follow-up of 5.8 months, 37 patients (66.1%) did
not require any LVP after the system implantation.
Of 127 post-implant paracenteses, 55 (43%) were related to
pump or catheter-related issues, such as clogging of the pump or
obstruction of the peritoneal catheter, dislocation or disconnection
of the catheters. The remaining LVPs were necessary due to techni-
cal issues with the charger or insufficient charging (10%), because
the programmed pumping volume was too low (27%), or for
unknown reasons in patients with normal pump function (20%)
(Table S5). Frequency of LVP per patient is displayed in Figure 4.
4 | DISCUSSION
The management of RA in patients with cirrhosis is challenging and
novel therapies are an unmet need in hepatology. The alfapump was
first introduced in 2010 as part of the PIONEER trial and has been
available commercially since 2011.20 The outcomes reported in that
initial series may have been influenced by the lack of previous expe-
rience with this device, potentially increasing the occurrence of pre-
ventable adverse events like infections and technical failures. Many
of these issues have now been addressed by process improvements
and continued development of the pump system.
This is the largest reported series to date of patients implanted
with an alfapump. The most frequently observed device deficiency
in this series was obstruction of the peritoneal catheter requiring
its exchange (21 events). Only 2 reinterventions were required for
issues related to the bladder catheter. Battery charging was a
minor issue with 2 chargers being replaced due to technical failure.
In this study, reintervention procedures were mostly simple, rapidly
performed and associated with a good outcome (Table 6).
Of note, that in the follow-up of patients with covered TIPSS, the
reintervention rate due to TIPSS dysfunction or hepatic encephalopa-
thy ranges, according to recent reports, from 7% to 42%18,26,27
TABLE 2 Paracentesis requirements and ascites volume removed by paracentesis and by alfapump system
Pre-implant Post-implant
Paracentesis frequency per month 48a patients 56 patients
Mean (SD, range) 2.88 (1.81, 0.5-10.1) 0.28 (0.34, 0-1.2)
Median (IQR) 2.17 (1.45-4.34) 0.17 (0-0.41)
Paracentesis volume (L per month) 45a Patients 51 patients
Litres per month, mean (SD, range) 19.3 (11.6, 3.9-53.2) 1.22 (1.67, 0-5.6)
Litres per month, Median (IQR) 16.3 (10.1-26.1) 0.41 (0-2.1)
Pump data
Average volume per patient removed by pump (mL/day) NA 55 patients
Mean (SD, range) NA 884 (398, 50-2051)
Median (IQR) NA 935 (625-1081)
Average volume per patient removed by pump per month (L per month) NA 55 patients
Mean (SD, range) NA 26.5 (11.9, 1.5-61.5)
Median (IQR) NA 28.1 (18.8-32.4)
aEvaluable patients. Baseline data not complete for all patients.
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F IGURE 2 A, Kaplan-Meier curve of overall survival (ITT) including known deaths after pump explant or withdrawal from study. B, Kaplan-
Meier curve of alfapump system survival
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depending on the duration of follow-up and technical characteristics
of the TIPSS. Moreover, patients with repeat LVP due to RA are reg-
ularly seen in out-patient clinics or, depending on the respective
country, even require short hospitalisations for the treatment of the
ascites. The large number of infections, in particular spontaneous
bacterial peritonitis (SBP) that occurred earlier prompted the decision
to use prophylactic antibiotics in all patients following implantation.20
Despite this precaution, bacterial infections occurred in roughly one-
third of patients included in the present study. The incidence of
infections is, however, similar to estimates of infection rates in cir-
rhotic patients who are hospitalised (25%-35% in recently published
series).28 In this context, it should be underlined that about 25% of
patients in this study had a very advanced stage of liver cirrhosis
(Child C), in which bacterial infections are known to occur very often
even in the absence of any intervention or device.
Nevertheless, some infections were clearly related to the pres-
ence of the device and prompted explantation of the pump system.
In particular, among the 17 pumps explanted due to SAEs, 2 cases
were related to pump pocket infections.
The results of this study show that the automated low-flow
ascites pump is effective in decreasing the need for LVP in patients
with RA by over 10-fold (from a median of 2.17 per month to 0.17
per month). Most patients treated with this system remained free of
LVP and the majority of paracenteses performed after the implanta-
tion of the pump system were necessary because of charger or pro-
gramming issues.
As for the survival observed in the present study, it is consis-
tent with that of patients undergoing LVP included in recent
TABLE 3 Disposition at data cut-off
Total enrolled (ITT/safety population) 56
Still on core treatment 3
Completed study (24-month follow-up) 3
Received liver transplant 9
Alfapump system no longer required
(spontaneous recovery after
anti-viral therapy of HCV with SVR)
1
Withdrawn due to SAEa 17
Subsequent deathb 7
Recovered 7
Outcome unknown 3
Deceased on study 23
Deceased overall 30
Median follow-up, months (range, IQR) 5.8 (0.7-26.4, 3.4-12.9)
Mean follow-up, months (SD) 8.31 (6.7)
aInfection (all cause), suspicion of infection, macrohaematuria, sepsis.
bComplications linked to liver disease; persistent liver insufficiency;
multi-organ failure.
TABLE 4 Causes of death in known mortality
N %
Progressive liver disease 15 50
Sepsis/infection 6 20
Renal failure 2 6.7
Post-TIPSS bleeding 1 3.3
Hepatocellular carcinoma 1 3.3
Stroke 1 3.3
Ischaemic heart disease 1 3.3
Perforated diverticulum 1 3.3
Unknown/other 2 6.7
Totala 30 100
aIncludes 7 deaths after subject withdrawal.
TABLE 5 Reasons for pump explantation
Pumps explanted 27
Adverse event/device deficiency 17
Clogged pump 1
Macroscopic haematuria 2
Infection 14
Peritonitis 5
Sepsis or suspicion of infectiona 5
Pump pocket infection 2
Urinary tract infection 1
Perforated diverticulum 1
Other 10
OLT 9
No longer requiredb 1
aNo infection subsequently found in 2 patients.
bPatient stopped producing ascites due to successful treatment for HCV.
TABLE 6 Outcome of revisional procedures
Number of procedures
(patients)
Reinterventions w/o pump
exchange or explantation
23 (17)
Recovereda 23 (17)
Died 0 (0)
Unknown 0 (0)
Pump exchange 12 (11)
Recovereda 11 (10)
Died 1 (1)
Unknown 0 (0)
Explantation 27 (27)
Recovered 18 (18)
OLT 9 (9)
No more needb 1 (1)
SAE, recovereda 8 (8)
SAE, died 6 (6)
Unknown 3 (3)
aOne-month survival.
bPatient stopped producing ascites due to successful treatment for HCV.
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studies for RA.2,29,30 To note, our survival data at 6 and
12 months were similar to those of patients treated with LVP in
a meta-analysis of trials investigating LVP vs TIPSS for RA.2 A
number of factors associated to a higher risk of mortality may
limit the use of TIPSS in patients with RA.15-17,19,31 They include
patient age >60,32 history of hepatic encephalopathy,15 and either
a platelet count below 75 9 109/L or a serum bilirubin
>50 lmol l1, and Child-Pugh C class.31 The results of a recent
study performed by Luca et al33 in patients with RA and a MELD
score below 12 (associated with a low procedural risk) confirm a
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F IGURE 3 Creatinine, bilirubin, albumin, INR, MELD and Child-Pugh scores over time
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high mortality in this population and show that anaemia, MELD
score and previous encephalopathy are negative prognostic factors
for the use of TIPSS. Therefore, the alfapump may be considered
an alternative to LVP in patients with RA for whom TIPSS is con-
traindicated. In this study, 31 patients (55.3%) were over 60 years
old and among those under 60, one-third were Child-Pugh C or
had a MELD score of 12 or above.
Clearly, the performance of the alfapump system will require a
direct comparison with that of TIPSS. A randomised controlled trial will
compare the efficacy and safety of PTFE-covered TIPSS vs alfapump
system vs repeated LVP in patients with cirrhosis and RA
(NCT02612519).
Regarding the drop of albumin levels after the implantation of
the alfapump, it has to be taken into account that prior to the
implantation albumin has been replaced on a regular basis in the
context of large volume paracenteses. A sub-analysis of albumin
levels covering the 6 months prior to the implantation of the pump
revealed that 50% of patients with an albumin level greater than
30 g/L at inclusion had levels below 30 g/L during the past
6 months before inclusion (data not shown).
Information on albumin substitution has been collected in the con-
text of paracentesis. Consequently, albumin-related information is
restricted to patients with at least 1 paracentesis after the implanta-
tion of the alfapump. The decision to administer albumin with the
pump system in place was taken on a case by case basis according to
the evaluation of each investigator. After the implantation of the pump
system, of 31 patients with LVP, 24 received at least one albumin sub-
stitution (maximum number of substitutions was 8 in 1 patient),
whereas in 7 patients no albumin replacement was reported.
During the follow-up period, we observed a moderate decrease
in serum albumin. This decrease can be explained at least partly by
the losses through the drained ascites and the gradual reduction in
the production of endogenous albumin related to the progression of
cirrhosis. Whether this decrease indeed was clinically relevant, can-
not be answered based on the available data on albumin.
During the follow-up, we also observed a mild increase in plasma
creatinine that was consistent at every time point and had already
been reported in the PIONEER study.20 In the randomised controlled
trial reported by Bureau et al,21 mean creatinine levels were slightly
higher in the alfapump treatment arm as well as in the standard of care
arm during follow-up compared with baseline, but these differences
were neither between nor within groups significant. In the alfapump
group, 30 adverse events with acute kidney injury were reported com-
pared to 11 events in the standard of care group. Of the 30 events in
the alfapump group, more than 40% occurred during the first week
after the implantation of the pump. Kidney function improved over
time in more than 70% of patients with acute kidney injury.
The increase in plasma creatinine observed in patients with an
alfapump system in place may reflect a decline in glomerular filtra-
tion rate, the mechanism of which cannot be ascertained from the
current observational study. A combination of a relative depletion of
intravascular blood volume in the setting of continuous drainage and
hypoalbuminaemia may contribute to explain the findings. The lack
of systematic albumin replacement may have aggravated effective
hypovolaemia that is known to occur in cirrhosis with ascites.
Clearly, future studies should include controlled use of albumin sub-
stitution, measurements of plasma renin activity, norepinephrine, and
natriuretic peptide to clarify these issues.34
For the interpretation of urinalysis, it is crucial to know whether
the urine is mixed with ascites or not. A common misinterpretation
in patients with an implanted alfapump is severe proteinuria that in
facts represents protein originating from the ascitic fluid.
Taking into account that most patients have their pump only dur-
ing daytime in operation mode, early morning urine can be used for
urinalysis. In case of relevant bacteria count in the urine, distinguish-
ing urinary tract infection from bacterial peritonitis might be difficult
and diagnostic paracentesis needed for confirmation or exclusion of
bacterial peritonitis. In critically ill patients with severely impaired
kidney function, the alfapump can be temporarily paused to have a
better control of urine output and composition.
The ideal patient for treatment with the alfapump system would
be a patient with RA that is otherwise in a relatively good condition,
ie presenting in a good nutritional status with normal kidney func-
tion, without relevant infection during the last months and a pre-
served liver function. Taking into account that a contraindication for
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TIPSS was a prerequisite for this observational study, most patients
had more advanced disease with additional cirrhosis-associated com-
plications at baseline like poor nutritional status, a history of SBP,
hepatic encephalopathy or hepatorenal syndrome.
Prior to the implantation of the alfapump, the diagnosis of RA
should be carefully reviewed by a hepatologist, as many of these
patients still have potential for improvement with conservative mea-
sures, ie optimisation of nutrition (low salt diet and adequate protein
intake, compensation for selective deficits, eg zinc) and diuretic ther-
apy (with a combination of an aldosterone antagonist and a loop
diuretic). Optimisation of nutrition is also beneficial for the reduction
of perioperative complication what has been shown in several other
surgical fields.35
Patients with a decreased renal function at baseline are at risk
for further deterioration of kidney function after the implantation of
the pump system and the decision to implant an alfapump should be
taken with caution.
Contraindications for the pump are active infection, especially
SBP or urinary tract infection, a life expectancy of less than
3 months, permanent confinement to bed, loculated ascites and uri-
nary outflow tract obstruction, unless treated successfully.
The limitations of this study include its observational design
without a direct comparison of the alfapump treatment with other
treatments that are considered as the current standard of care. In
addition, the long-term management of patients was left to the dis-
cretion of the treating physicians and did not follow a predefined
protocol that was common for all participating centres, nor did it
require that all patients in each centre be enrolled in the registry.
However, procedure-related events were collected in a standardised,
prospective way. Therefore, the device deficiency data are robust.
Quality-of-life data were not collected and the available data on
albumin substitution in the context of paracenteses preclude the
determination of meaningful correlations with serum albumin. Cur-
rently, the pump is marketed in the EU, in Switzerland and in Israel,
and the cost for the pump in the EU is 25 000€. Health-related
costs, however, were not specifically addressed in this study.
In conclusion, the data presented here show that the alfapump
system for the management of patients with RA and contraindica-
tions for TIPSS offers good efficacy, leading to an over 10-fold
reduction in the need for LVP under real-world conditions. Technical
and procedural improvements are required to reduce the rate of
adverse events and reinterventions. Optimisation of the system is
ongoing, and preliminary results of a new version of the peritoneal
catheter show a markedly decreased rate of catheter-related compli-
cations. Remaining open issues include the effects on quality of life
and liver function and the role of albumin replacement with its effect
on relative volume status.
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